![]() | David JayneLeeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, UK | The John Goligher Colorectal Surgery Unit, St. James's University ... |
KOL Resume for David Jayne
Year | |
---|---|
2022 | Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, UK University of Cambridge for the TESTING Study Group |
2021 | Division of Nephrology, Department of Medicine, University of Cambridge, Cambridge, UK |
2020 | Medicine, University of Cambridge, Cambridge, UK University of CAMBRIDGE Europian Vasculitis Society |
2019 | University of Cambridge Addenbrookes Hospital Cambridge, United Kingdom United States Navy, Gulfport, MS, USA |
2016 | Dept of Medicine, University of Cambridge, UK |
2015 | University of Cambridge, Department of Medicine, Cambridge, UK. |
2013 | Addenbrooke's Hospital Lupus and Vasculitis Clinic CUHNHSFT, Cambridge UK |
2009 | Chief, Division of Nephrology and Hypertension University of North Carolina Chapel Hill, North Carolina Professor of Medicine, University of Utah and Veternas Affairs, Salt Lake City Healthcare System DJ Thurston Professsor O Medicine Director, UNC Kidney Center |
2007 | UTC Power |
2005 | Chemical Engineering Department, Environmental Engineering Program, University of Connecticut, Storrs, CT 06269, USA |
1999 | Australian Bureau of Statistics, 313 Adelaide Street Brisbane, QLD, 4000 |
David Jayne: Influence Statistics
Concept | World rank |
---|---|
vasculitis plasma exchange | #5 |
cardiovascular p120 | #7 |
patient cmavm | #8 |
report cmavm | #8 |
financial therapists | #13 |
mutation rasgap | #20 |
archuleta | #21 |
– avm | #21 |
development egpa | #22 |
financial anxiety | #22 |
– arteriovenous | #37 |
years egpa | #48 |
patients definite vasculitis | #48 |
rasgap domain | #49 |
criteria egpa | #49 |
cases egpa | #55 |
anca testing patients | #55 |
malformation – | #61 |
consensus anca | #64 |
financial therapy | #66 |
egpa asthma | #71 |
manifestations eosinophilic | #72 |
rasa1 mutation | #73 |
diagnosis egpa | #75 |
polyangiitis eosinophilic granulomatosis | #79 |
polyangiitis hepatitis | #80 |
egpa diagnosis | #82 |
patients polyangiitis | #82 |
diesel adsorption | #86 |
vasculitis eosinophilic | #86 |
vasculitis features | #86 |
anca tested | #86 |
management pmr | #90 |
study egpa | #96 |
definite vasculitis | #96 |
polyangiitis churgstrauss | #97 |
Open the FULL List in Excel | |
Prominent publications by David Jayne
OBJECTIVES: The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.
METHODS: Twenty-one SLE ...
Known for Early Disease | Acr Criteria | Sensitivity Specificity | Systemic Lupus | 2019 Eular |
OBJECTIVE: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA.
METHODS: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease.
RESULTS: The study population ...
Known for Systemic Vasculitis | Eosinophilic Granulomatosis | Anca Patients | Polyangiitis Egpa | Mononeuritis Multiplex |
This document follows up on a 2017 revised international consensus on anti-neutrophil cytoplasm antibodies (ANCA) testing in granulomatosis with polyangiitis and microscopic polyangiitis and focuses on the clinical and diagnostic value of ANCA detection in patients with connective tissue diseases, idiopathic interstitial pneumonia, autoimmune liver diseases, inflammatory bowel diseases, anti-glomerular basement membrane (GBM) disease, infections, malignancy, and during drug treatment. ...
Known for Anca Testing | International Consensus | Autoimmune Liver Diseases | Infective Endocarditis | Ulcerative Colitis |
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
[ PUBLICATION ]
BACKGROUND/OBJECTIVES: The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus system showed high specificity, while attaining also high sensitivity. We hereby analysed the performance of the individual criteria items and their contribution to the overall performance of the criteria.
METHODS: We combined the EULAR/ACR derivation and validation cohorts for a total of 1197 systemic lupus ...
Known for European League | Classification Criteria | Sensitivity Performance | Rheumatology Acr | Attribution Rule |
Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
[ PUBLICATION ]
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma ...
Known for Eosinophilic Granulomatosis | Egpa Asthma | Polyangiitis Humans | Patients Diagnosis | 3 Years |
Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the ...
Known for Polymyalgia Rheumatica | Patients Pmr | European League | Recommendations Management | Glucocorticoids Humans |
Dynamics of removal of organosulfur compounds from diesel by adsorption on carbon aerogels for fuel cell applications
[ PUBLICATION ]
Carbon aerogels (CAs) were investigated as adsorbents for the desulfurization of liquid hydrocarbon fuels for fuel cell applications. Synthetic mixtures of dibenzothiophene (DBT) and 4,6-dimethyldibenzothiophene (4,6-DMDBT) in n-hexadecane (n-HD) were used as models for sulfur contaminated diesel fuel. Carbon aerogels were found to have good adsorption capacity for both DBT and 4,6-DMDBT. Both the thermodynamics and dynamics of adsorption were investigated by the measurement of ...
Known for Fuel Cell Applications | Adsorption Dbt | Carbon Aerogels | Organosulfur Compounds | Pore Size |
A novel RASA1 mutation causing capillary malformation–arteriovenous malformation (CM–AVM) presenting during pregnancy
[ PUBLICATION ]
Capillary malformation-arteriovenous malformation (CM-AVM) is a newly recognized clinical entity caused by mutation of the RASA1 gene, which encodes p120-RasGAP. Here we describe, for the first time, a patient with CM-AVM presenting during the late stages of pregnancy with pulmonary "capillary level" microvascular shunt, worsening cutaneous capillary malformations, and gross fluid overload. Sequencing revealed a novel mutation of the RASA1 gene involving a frameshift mutation in the ...
Known for Rasa1 Mutation | Capillary Malformation | Rasgap Domain | Report Cmavm | Avm Pregnancy |
2021 DORIS definition of remission in SLE: final recommendations from an international task force
[ PUBLICATION ]
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS).
BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation.
METHODS: Several systematic literature reviews were performed and specific research questions ...
Known for Remission Sle | Task Force | Lupus Erythematosus | Global Assessment |
Financial Goal Setting, Financial Anxiety, and Solution-Focused Financial Therapy (SFFT): A Quasi-experimental Outcome Study
[ PUBLICATION ]
Financial anxiety appears to have a significant effect on the lives of many Americans (APA Stress in America™, paying with our health, American Psychological Association, Washington, DC, 2015) and a source of client distress among mental health clinicians, financial professionals, and financial therapists. Solution-Focused Brief Therapy (SFBT) has been utilized in number disciplines as a way to help professionals interact with clients to create change and improve well-being. This study ...
Known for Financial Anxiety | Mental Health Clinicians | Focused Therapy | Study Utilized |
OBJECTIVE: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).
METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel ...
Known for Eosinophilic Granulomatosis | Classification Criteria | Polyangiitis Egpa | Cytoplasmic Antibody | Vessel Vasculitis |
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
[ PUBLICATION ]
OBJECTIVE: To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis.
METHODS: This phase II double-blinded study randomised 147 patients (1:1:1) to receive monthly intravenous anifrolumab basic regimen (BR, 300 mg), intensified regimen (IR, 900 mg ×3, 300 mg thereafter) or placebo, alongside standard therapy (oral glucocorticoids, mycophenolate mofetil). The primary endpoint was change ...
Known for Lupus Nephritis | Mycophenolate Mofetil | Patients Active | Type Interferon | Herpes Zoster |
OBJECTIVE: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).
METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases ...
Known for Classification Criteria | Granulomatosis Polyangiitis | Cytoplasmic Antibody | Small Medium | Vessel Vasculitis |
OBJECTIVE: To develop and validate classification criteria for microscopic polyangiitis (MPA).
METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference ...
Known for Microscopic Polyangiitis | Classification Criteria | Cytoplasmic Antibody | Vessel Vasculitis | Small Medium |
Key People For Eosinophilic Granulomatosis
David Jayne:Expert Impact
Concepts for whichDavid Jaynehas direct influence:Eosinophilic granulomatosis, Systemic vasculitis, Plasma exchange, Financial anxiety, European league, Systemic lupus erythematosus, Patients aav, Classification criteria.
David Jayne:KOL impact
Concepts related to the work of other authors for whichfor which David Jayne has influence:Eosinophilic granulomatosis, Polymyalgia rheumatica, Systemic lupus erythematosus, Carbon xerogels, Polyangiitis egpa, Giant cell arteritis, Classification criteria.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |